Swiss Trial Tests Adjunctive Linezolid for a Deadly Bloodstream Infection
Staphylococcus aureus bacteraemia remains one of the most feared infections in hospital medicine because the organism is both aggressive and adaptable. Mortality still ranges from 20% to 30%, and more than a third of survivors live with long-term impairment. Standard therapy clears many bloodstream infections, yet the clinical burden after apparent microbiological control often stays high, driven by metastatic complications, organ dysfunction, prolonged hospitalization, and slow functional recovery. This trial protocol takes aim at that gap by asking a focused question: can a short adjunctive course of linezolid improve outcomes that patients actually feel and experience, not just laboratory markers of infection control?
The study is designed as a two-arm, parallel-group, multicentre randomized controlled trial across 12 hospitals in Switzerland. Treating physicians, patients, and outcome assessors will be blinded, which is essential in a condition where clinical judgment can easily be influenced by knowledge of treatment allocation. Adult inpatients with S. aureus bacteraemia are eligible, and randomization must occur within 72 hours of collection of the blood sample that yielded the first positive culture. Participants will continue standard antibiotic treatment as determined by the treating physician and then receive either adjunctive linezolid or placebo.
A 5-day oral regimen of 600 mg twice daily was selected. The dose is familiar from established use in pneumonia and complicated skin infection, but the rationale here is different: linezolid may do more than inhibit bacterial growth. Preclinical work suggests it can suppress virulence factors linked to persistence and tissue damage, a biologically plausible strategy in a pathogen that harms hosts through both invasion and toxin-mediated inflammation. In bloodstream infection, where dissemination can occur quickly, limiting virulence expression may matter as much as reducing bacterial burden itself.
Why the Trial Uses DOOR Instead of a Single Conventional Endpoint
The primary endpoint is the desirability of outcome ranking, or DOOR, measured at 90 days. This is not a simplistic cure-versus-no-cure design. Instead, outcomes are ranked hierarchically from most to least desirable across four domains: survival, return to pre-infection function, complications that lead to treatment changes and serious adverse reactions, and hospital length of stay. The hierarchy reflects a clinical truth that matters in S. aureus infection: survival is crucial, but survival alone does not capture the full burden of disease or treatment toxicity.
Using DOOR also changes what counts as success. A patient who survives but never regains baseline function, requires repeated antibiotic changes because of complications, or remains hospitalized for a prolonged period has not had a truly favorable course. The win-ratio framework built into this endpoint compares whether patients assigned to linezolid achieve a more favorable overall rank than those receiving placebo. For a syndrome as heterogeneous as bacteraemia, that structure may better reflect bedside decision-making than a narrow binary endpoint.
One sentence captures the central gamble of the trial: adjunctive immunobiology-driven therapy may improve a complex infection even when conventional antibiotic coverage is already in place.
Patient Selection, Masking, and Ethical Safeguards
The trial enrolls hospitalized adults aged 18 years or older, which keeps the study focused on the population where the mortality and complication burden is greatest. Randomization within 72 hours of the first positive culture should capture the period when host-pathogen interactions are still actively shaping the course of disease. The multicentre design across Swiss hospitals increases feasibility and should help recruit a broad inpatient population, although the protocol does not claim to resolve all clinical heterogeneity in one study.
Masking extends to physicians, patients, and outcome assessors. In a trial of adjunctive antibiotics, that level of blinding is especially important because expectations can influence decisions about duration of hospitalization, additional testing, or treatment changes. The protocol also includes a patient-representative consultation process in the development of the primary outcome, which is a meaningful step for a condition that often leaves survivors with fatigue, reduced mobility, and delayed recovery long after the bloodstream has cleared.
Ethical approval was obtained from the Ethics committee for Northern and Central Switzerland, and the protocol allows for substitute decision-making when patients are unable to provide informed consent. A close relative or an uninvolved physician may act based on presumed wishes and best interests, with the patient’s own consent sought later if condition permits. That approach is particularly relevant in severe sepsis and bacteraemia, where clinical instability may temporarily remove the ability to participate in enrollment decisions.
The Biological Logic Behind a Short Adjunctive Course
Linezolid is already a familiar antimicrobial, but its proposed role here is not simply as another bactericidal or bacteriostatic agent added to the regimen. The investigational premise is that suppressing virulence pathways may reduce tissue damage, dampen persistence, and blunt the downstream inflammatory cascade that makes S. aureus so destructive. In bloodstream infection, the host response can become as harmful as the organism itself, particularly when infection seeds bone, valves, joints, or other deep sites.
A 5-day adjunctive course is also clinically interesting because it limits exposure while targeting the early phase of infection when bacterial signaling and host injury are most active. If the intervention works, the benefit may appear not as dramatic microbiological sterilization but as fewer complications, fewer treatment changes, and better functional recovery at 90 days. If it fails, the trial will still clarify whether the pathophysiological rationale translates into measurable patient benefit in routine hospital care.
Sample Size, Power, and What the Study Can and Cannot Answer Yet
The planned sample size is 606 patients, with 90% power at a two-sided significance level of 0.05. That is a substantial randomized effort for a pathogen-specific adjunctive therapy trial, and it gives the study a reasonable chance to detect a clinically meaningful shift in the composite rank outcome. The trial is registered under NCT06958835, and results are slated for publication in peer-reviewed journals as well as lay summaries through public channels.
Even so, the protocol leaves important questions open. The study is designed to test whether adjunctive linezolid improves the global course of illness, not whether every subgroup benefits equally or whether the effect is strongest in specific syndromes within the broader bacteraemia population. It also cannot yet determine how any observed benefit will balance against adverse reactions when linezolid is added to standard treatment. Those are precisely the issues the randomized design is meant to address, but the answer will only come after enrollment and follow-up are complete.
For now, the protocol marks a careful attempt to move beyond infection clearance alone and measure whether an adjunctive strategy can improve survival, recovery, complications, and hospital trajectory in one of medicine’s most consequential bloodstream infections.